CYCN — Cyclerion Therapeutics Share Price
0.000.00%
Last trade - 00:00- $10.09m
- $6.86m
- $2.00m
- 26
- 32
- 64
- 35
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.14 | ||
| Price to Tang. Book | 1.14 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 5.05 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -36.89% | ||
| Return on Equity | -30.36% | ||
| Operating Margin | -163.25% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2.3 | 3.94 | 0.3 | n/a | 2 | n/a | n/a | -15% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
Directors
- Marsha Fanucci NEC (67)
- Peter Hecht CEO (57)
- Cheryl Gault COO (42)
- Andreas Busch CSO (57)
- George Conrades IND (82)
- Errol De Souza IND (67)
- Ole Isacson IND (61)
- Stephanie Lovell IND (61)
- Terrance McGuire IND (65)
- Michael Mendelsohn IND (65)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 6th, 2018
- Public Since
- March 18th, 2019
- No. of Shareholders
- 51
- No. of Employees
- 1
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 3,210,094
- Address
- 301 Binney Street, CAMBRIDGE, 02142
- Web
- https://www.cyclerion.com/
- Phone
- +1 6176217722
- Auditors
- Ernst & Young LLP
Upcoming Events for CYCN
Cyclerion Therapeutics Inc Annual Shareholders Meeting
Cyclerion Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Cyclerion Therapeutics Inc Earnings Release
Similar to CYCN
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Cyclerion Therapeutics share price?
As of Today at 20:09 UTC, shares in Cyclerion Therapeutics are trading at $3.14. This share price information is delayed by 15 minutes.
How has the Cyclerion Therapeutics share price performed this year?
Shares in Cyclerion Therapeutics last closed at $3.14 and the price had moved by +11.51% over the past 365 days. In terms of relative price strength the Cyclerion Therapeutics share price has outperformed the S&P500 Index by +0.55% over the past year.
What are the analyst and broker recommendations for Cyclerion Therapeutics?
The overall consensus recommendation for Cyclerion Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Cyclerion Therapeutics dividend yield?
Cyclerion Therapeutics does not currently pay a dividend.
Does Cyclerion Therapeutics pay a dividend?
Cyclerion Therapeutics does not currently pay a dividend.
When does Cyclerion Therapeutics next pay dividends?
Cyclerion Therapeutics does not currently pay a dividend.
How do I buy Cyclerion Therapeutics shares?
To buy shares in Cyclerion Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cyclerion Therapeutics?
As of the previous close price of $3.14, shares in Cyclerion Therapeutics had a market capitalisation of $10.09m.
Where are Cyclerion Therapeutics shares listed?
Here are the trading details for Cyclerion Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CYCN
What kind of share is Cyclerion Therapeutics?
Based on an overall assessment of its quality, value and momentum Cyclerion Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cyclerion Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Cyclerion Therapeutics is $4.00. That is 27.21% above the last closing price of $3.14.
Analysts covering Cyclerion Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Cyclerion Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cyclerion Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +7.08%.
As of the last closing price of $3.14, shares in Cyclerion Therapeutics were trading +8.3% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cyclerion Therapeutics PE Ratio?
The Cyclerion Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.14.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cyclerion Therapeutics?
Cyclerion Therapeutics' management team is headed by:
- Marsha Fanucci - NEC
- Peter Hecht - CEO
- Cheryl Gault - COO
- Andreas Busch - CSO
- George Conrades - IND
- Errol De Souza - IND
- Ole Isacson - IND
- Stephanie Lovell - IND
- Terrance McGuire - IND
- Michael Mendelsohn - IND